PSMA PET/CT SUVmax as a prognostic biomarker in patients with metachronous metastatic hormone-sensitive prostate cancer (mHSPC)
I. Henrı́quez, Bárbara Malavé, Fernando López‐Campos, Elena Centelles Hidalgo, R. Muelas, C. Ferrer, Jesús Muñoz-Rodríguez, A. Méndez Villamón, María Cerrolaza Pascual, Joan R. Badia, Jordi Fuertes, Percy Hinojosa-Salas
Topics & Concepts
MedicineProstate cancerOncologyInternal medicineBiomarkerPET-CTCancerNuclear medicinePositron emission tomographyBiochemistryChemistryProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications